Literature DB >> 8010937

Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: a comparison to its S-enantiomer BDF 9196, to its congener DPI 201-106, to norepinephrine, and to ouabain.

D Baumgart1, T Ehring, M Krajcar, A Skyschally, G Heusch.   

Abstract

Positive inotropic substances which enhance the myocardial cAMP level or inhibit the Na+/K(+)-ATPase are known for their proarrhythmic side-effects. This study was performed to investigate the inotropic and arrhythmogenic action of the Na(+)-channel activator BDF 9148 (racemate) in comparison to its S-enantiomer BDF 9196, its congener DPI 201-106 (racemate), to norepinephrine, and to ouabain. In 30 open-chest dogs, the effects of these substances on the first derivative of left ventricular pressure (dP/dt, Millar-tip catheter) and anterior systolic wall thickening (AWT, sonomicrometry) were studied. Concomitantly, myocardial excitability, conduction times, and refractory period were assessed with a transmural, three-dimensional, 16-electrode array in the anterior wall. For the study of the Na(+)-channel activators, alpha- and beta-adrenergic and muscarinic receptors were blocked. A first set of measurements was performed during normoperfusion with administration of BDF 9148 (1 mg/kg, n = 8), BDF 9196 (0.5 mg/kg, n = 8), and DPI 201-106 (1 mg/kg, n = 8), respectively. A second set of measurements was performed with administration of the threefold dosage of either substance. With a severe stenosis on the left anterior descending coronary artery, a final set of measurements was performed, again using the higher dosage of either substance. For the study of norepinephrine (0.5 micrograms/kg/min i.v., n = 6) and ouabain (40 micrograms/kg i.v., n = 4), measurements were performed during normoperfusion in additional animals. Under normal conditions, either Na(+)-channel activator induced increases in dP/dtmax (lower dosage: 45-84%, higher dosage: by 93-117%) and AWT (lower dosage: by 24-37%, higher dosage: by 19-56%). Under ischemic conditions, either drug increased dP/dtmax by 60-98% and AWT by 45-102%. Excitability, conduction times, and refractory period did not change significantly in response to the Na(+)-channel activators, neither under normal nor under ischemic conditions. There was no significant difference in the incidence of spontaneous ventricular extrasystoles before and after administration of either Na(+)-channel activator. In contrast, an equi-inotropic dosage of norepinephrine (increases in dP/dtmax by 148% and AWT by 42%) increased excitability, decreased conduction times and refractory period, and increased the incidence of spontaneous ventricular extrasystoles. Ouabain induced only a moderate increase in dP/dtmax by 56% and AWT by 24%, but elicited sustained and complex ventricular arrhythmias. Excitability was markedly increased, whereas conduction times and refractory period changed only little.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8010937     DOI: 10.1007/bf00788678

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  37 in total

1.  [Electrophysiological measurement of strophanthin effects on heart muscle].

Authors:  J DUDEL; W TRAUTWEIN
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1958

2.  Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation.

Authors:  R Schulz; B D Guth; K Pieper; C Martin; G Heusch
Journal:  Circ Res       Date:  1992-06       Impact factor: 17.367

Review 3.  The pharmacologic treatment of chronic congestive heart failure.

Authors:  S H Rahimtoola
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

4.  Mechanisms of digitalis toxicity. Effects of ouabain on phase four of canine Purkinje fiber transmembrane potentials.

Authors:  M R Rosen; H Gelband; C Merker; B F Hoffman
Journal:  Circulation       Date:  1973-04       Impact factor: 29.690

5.  CORDAT II: a new program for data acquisition and on-line calculation of hemodynamic and regional myocardial dimension parameters.

Authors:  A Skyschally; R Schulz; G Heusch
Journal:  Comput Biol Med       Date:  1993-09       Impact factor: 4.589

6.  Regional myocardial function during acute coronary artery occlusion and its modification by pharmacologic agents in the dog.

Authors:  P Theroux; D Franklin; J Ross; W S Kemper
Journal:  Circ Res       Date:  1974-12       Impact factor: 17.367

7.  DPI 201-106 for severe congestive heart failure.

Authors:  J B Kostis; C R Lacy; J J Raia; J H Dworkin; R G Warner; L A Casazza
Journal:  Am J Cardiol       Date:  1987-12-01       Impact factor: 2.778

8.  Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term effects and lack of tolerance.

Authors:  H H Erlemeier; W Kupper; W Bleifeld
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

9.  The time courses of the changes in contractile force and in transmembfane potentials induced by cardiac glycosides in guinea-pig papillary muscle.

Authors:  H Lüllmann; U Ravens
Journal:  Br J Pharmacol       Date:  1973-11       Impact factor: 8.739

10.  Phosphodiesterase-inhibiting properties of newer inotropic agents.

Authors:  H Scholz; W Meyer
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

View more
  1 in total

Review 1.  Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure.

Authors:  H N Sabbah; W Haddad; Y Mika; O Nass; R Aviv; V G Sharov; V Maltsev; B Felzen; A I Undrovinas; S Goldstein; N Darvish; S A Ben-Haim
Journal:  Heart Fail Rev       Date:  2001-01       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.